Robot-Assisted Radical Prostatectomy in Hong Kong: A Review of 235 Cases

Yip, Kwok Ho; Yee, Chi‐Hang; Ng, Chi‐Fai; Lam, Nga-Yee; Ho, Ka Yan; Ma, Wai‐Kit; Li, Cheuk-man; Hou, See‐Ming; Tam, Po‐Chor; Yiu, MK; Fan, Cho-wai

doi:10.1089/end.2011.0303

Cited by 21 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Caseloads from the public hospitals in Hong Kong account for the majority of RALP in Hong Kong. In the early development of the RALP programme in Hong Kong, Yip et al (10) reported that 74.9% of patients with RALP had pT2 disease, and 23.4% with pT3 disease. Overall trifecta rate at 12 months was 37.3%.…”

Section: Prostate Cancermentioning

confidence: 99%

Urological malignancy in Hong Kong: the trend and the practice

Yee

2015

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Prostate Cancermentioning

confidence: 99%

Urological malignancy in Hong Kong: the trend and the practice

Yee

2015

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…14,15 However, there is a paucity of data in terms of RARP long-term oncological outcomes in Asian cohorts. [16][17][18] Regarding the clinical and pathological T-stage, notably, the current study showed that the presence of ≥cT2c and pT3 were associated with lower a incidence of 5-year BCRFS (50.7% and 58.6%, respectively); in addition, ≥cT2c (HR 2.26, 95% CI 1.66-3.07; P < 0.001) and pT3 (HR 1.48, 95% CI 1.04-2.11; P = 0.032) were significant predictors of BCR on multivariate analysis. These results emphasize the prognostic importance and unfavorable consequences in case of proven seminal vesicle and/or extra-capsular extension during staging process.…”

Section: Discussionmentioning

confidence: 99%

Stratified analysis of 800 Asian patients after robot‐assisted radical prostatectomy with a median 64 months of follow up

et al. 2016

View full text Add to dashboard Cite

Objective: To report the 5-year oncological outcomes of robot-assisted radical prostatectomy from the largest series ever reported from Asia. Methods: A retrospective analysis of 800 Asian patients who were treated with robotassisted radical prostatectomy from July 2005 to May 2010 in the Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea was carried out. The primary end-point was to evaluate the biochemical recurrence. The secondary end-point was to show the biochemical recurrence-free survival, metastasisfree survival and cancer-specific survival. Results: A total of 197 (24.65%), 218 (27.3%), and 385 (48.1%) patients were classified as low-, intermediate-and high-risk patients according to the D'Amico risk stratification risk criteria, respectively. The median follow-up period was 64 months (interquartile range 28-71 months). The overall incidence of positive surgical margin was 36.6%. There was biochemical recurrence in 183 patients (22.9%), 38 patients (4.8%) developed distant metastasis and 24 patients (3%) died from prostate cancer. Actuarial biochemical recurrence-free survival, metastasis-free survival, and cancer-specific survival rates at 5 years were 76.4%, 94.6% and 96.7%, respectively. Positive lymph node was associated with lower 5-year biochemical recurrence-free survival (9.1%), cancer-specific survival (75.7%) and metastasis-free survival (61.9%) rates (P < 0.001). On multivariable analysis, among all the predictors, positive lymph node was the strongest predictor of biochemical recurrence, cancer-specific survival and metastasis-free survival (P < 0.001). Conclusions: Herein we report the largest robot-assisted radical prostatectomy series from Asia. Robot-assisted radical prostatectomy is confirmed to be an oncologically safe procedure that is able to provide effective 5-year cancer control, even in patients with high-risk disease.

show abstract

“…8 With regards to the oncologic outcomes after RARP, there are only a few Asian studies, and most have short-term follow-up. Recently, Yip et al 36 reported 235 patients treated with RARP between 2005 and 2009 in Hong Kong, China. However, the mean follow-up period was 24 months and the biochemical outcomes were not analysed in detail.…”

Section: Discussionmentioning

confidence: 99%

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Kim¹,

Lim²,

Shin³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November 2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59-69). The median prostate specific antigen was 7.50 ng ml 21 (IQR: 5.14-11.45) and 39.2% of the patients were classified as intermediate risk and 15.3% were classified as high risk; on final pathological examination, 35.2% of the patients had non-organ confined disease and 37.5% and 14.2% had Gleason scores of 7 and 8-10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were 85.6% and 81.2%, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1% in Gleason scores of 6 or less, 74.5% in a Gleason score of 7, and 58.1% in Gleason scores of 8 or greater, respectively (P,0.001). When stratified by pathologic stage, the BCR-free survival rates were 89.8% in pT2 patients, 66.2% in pT3a patients, and 39.3% in pT3b patients at 5 years following RARP, respectively (P,0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.

show abstract

Robot-Assisted Radical Prostatectomy in Hong Kong: A Review of 235 Cases

Abstract: Our data demonstrate the feasibility, safety, and efficacy of RALP in low-to-intermediate volume centers. Our early oncologic outcomes were significantly correlated with pathologic stage and D'Amico risk stratification.

Cited by 21 publications

References 30 publications

Urological malignancy in Hong Kong: the trend and the practice

Urological malignancy in Hong Kong: the trend and the practice

Stratified analysis of 800 Asian patients after robot‐assisted radical prostatectomy with a median 64 months of follow up

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Contact Info

Product

Resources

About